Genmab A (GMAB) Liabilities and Shareholders Equity (2018 - 2026)

Genmab A (GMAB) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $12.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 93.61% year-over-year to $12.5 billion; the trailing twelve-month figure through Jun 2026 stood at $38.7 billion (up 83.09% YoY), and the FY2025 full-year result was $12.9 billion, up 202.02% from the prior year.
• Liabilities and Shareholders Equity advanced to $12.5 billion in Q2 2026 per GMAB's latest filing, from $12.4 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $12.9 billion in Q4 2025 and bottomed at $904.2 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $5.0 billion across 5 years, with a median of $3.5 billion in 2024.
• The widest YoY moves for Liabilities and Shareholders Equity: up 202.02% in 2025, down 76.25% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.9 billion in 2022, then advanced by 15.8% to $3.3 billion in 2023, then grew by 28.57% to $4.3 billion in 2024, then jumped by 202.02% to $12.9 billion in 2025, then slipped by 2.78% to $12.5 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $12.5 billion, $12.4 billion, and $12.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.